论文部分内容阅读
最近在法国开展的肿瘤标记物试验证实有可以精确预测几种癌症预后的方法。 1982年美国开展脂联唾液酸(LASA)试验,但目前在加拿大和美国仍只能用作实验的基础。法国Villejuif PaulBrosse医院的Marina Mus-set说,LASA试验是以病人血浆样品的实验室评定为基础,这是肿瘤学医师非常有用的工具。试验证明此方法可用于淋巴瘤、鳞状细胞癌、乳腺癌、前列腺癌和恶性黑色素瘤病人。在148名何杰金氏或非何杰金氏淋巴瘤患者中,虽然LASA
Recent tumor marker tests conducted in France have demonstrated methods that can accurately predict the prognosis of several cancers. In 1982, the United States conducted a lipid-linked sialic acid (LASA) trial, but it can still only be used as a basis for experiments in Canada and the United States. The Marina Mus-set at Villejuif PaulBrosse Hospital in France stated that the LASA trial is based on the laboratory assessment of patient plasma samples, which is a very useful tool for oncologists. Tests have shown that this method can be used for lymphoma, squamous cell carcinoma, breast cancer, prostate cancer and malignant melanoma patients. Among 148 patients with Hodgkin’s or non-Hodgkin’s lymphoma, LASA